Research progress of peripheral blood free DNA in preeclampsia pregnancy

Abstract

Abstract: Pregnancy-induced hypertension, especially preeclampsia (PE), is one of the leading causes of increased maternal and perinatal morbidity and mortality worldwide. And the circulating cell free fetal nucleic acid (cff-DNA) analysis of pregnant women can be used as an early prediction of the occurrence and development of PE. By summarizing and analyzing the correlation between cff-DNA and PE and its possible mechanism, this paper further explained that the occurrence of PE may be related to DNA methylation, and discussed its limitations as a biomarker, so as to provide reference for the effective prediction of preeclampsia.

Key words: cell free fetal nucleic acid, preeclampsia, biomarker

CLC Number:

R714
R44

ZHOU Jia-yi, WU Xun-wei, DAI Li-juan, ZHAO Gui-li, YU Bo-lan. Research progress of peripheral blood free DNA in preeclampsia pregnancy[J]. Basic & Clinical Medicine, 2020, 40(12): 1701-1705.

References

[1] Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implications of fetal-maternal lymphocyte transfer[J]. Lancet, 1969, 1: 1119-1122.
[2] Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum[J]. Lancet, 1997, 350: 485-487.
[3] Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines[J]. PLoS One, 2014, 9: e113715.doi: 10.1371/journal.pone.0113715.
[4] Bender WR, Koelper NC, Sammel MD, et al. Association of fetal fraction of cell-free DNA and hypertensive disorders of pregnancy[J]. Am J Perinatol, 2019, 36: 311-316.
[5] Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP[J]. Pregnancy Hypertens, 2014, 4: 97-104.
[6] Granger JP, Alexander BT, Bennett WA, et al. Pathophysiology of pregnancy-induced hypertension[J]. Am J Hypertens, 2001, 14: 178s-185s.
[7] Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia[J]. Front Biosci, 2007, 12: 2395-2402.
[8] Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia[J]. Lancet, 2016, 387: 999-1011.
[9] Naljayan MV, Karumanchi SA. New developments in the pathogenesis of preeclampsia[J]. Adv Chronic Kidney Dis, 2013, 20: 265-270.
[10] Kohli S, Ranjan S, Hoffmann J, et al. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts[J]. Blood, 2016, 128: 2153-2164.
[11] He B, Yang X, Li Y, et al. TLR9 (Toll-Like Receptor 9) agonist suppresses angiogenesis by differentially regulating VEGFA (vascular endothelial growth factor A) and sFLT1 (soluble vascular endothelial growth factor receptor 1) in preeclampsia[J]. Hypertension, 2018, 71: 671-680.
[12] van Boeckel SR, Davidson DJ, Norman JE, et al. Cell-free fetal DNA and spontaneous preterm birth[J]. Reproduction, 2018, 155: R137-R145.
[13] Sur Chowdhury C, Hahn S, Hasler P, et al. Elevated levels of total cell-free DNA in maternal serum samples arise from the generation of neutrophil extracellular traps[J]. Fetal Diagn Ther, 2016, 40: 263-267.
[14] Eche S, Mackraj I, Moodley J. Circulating fetal and total cell-free DNA, and sHLA-G in black South African women with gestational hypertension and pre-eclampsia[J]. Hypertens Pregnancy, 2017, 36: 295-301.
[15] Vinnars MT, Nasiell J, Ghazi S, et al. The severity of clinical manifestations in preeclampsia correlates with the amount of placental infarction[J]. Acta Obstet Gynecol Scand, 2011, 90: 19-25.
[16] Rolnik DL, da Silva Costa F, Lee TJ, et al. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia[J]. Ultrasound Obstet Gynecol, 2018, 52: 722-727.
[17] Poon LL, Leung TN, Lau TK, et al. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma[J]. Clin Chem, 2002, 48: 35-41.
[18] Majchrzak-Celinska A, Kosicka K, Paczkowska J, et al. HSD11B2, RUNX3, and LINE-1 methylation in placental DNA of hypertensive disorders of pregnancy patients[J]. Reprod Sci, 2017, 24: 1520-1531.
[19] Chen X, Xiong L, Zeng T, et al. Hypermethylated ERG as a cell-free fetal DNA biomarker for non-invasive prenatal testing of Down syndrome[J]. Clin Chim Acta, 2015, 444: 289-292.
[20] Dokras A, Gardner LM, Kirschmann DA, et al. The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development[J]. Placenta, 2002, 23: 274-280.
[21] Chim SS, Tong YK, Chiu RW, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma[J]. Proc Natl Acad Sci U S A, 2005, 102: 14753-14758.
[22] Shi X, Liu H, Cao J, et al. Promoter hypomethylation of maspin inhibits migration and invasion of extravillous trophoblast cells during placentation[J]. PLoS One, 2015, 10: e0135359.doi:10.1371/joumal.pone.0135359.
[23] Qi YH, Teng F, Zhou Q, et al. Unmethylated-maspin DNA in maternal plasma is associated with severe preeclampsia[J]. Acta Obstet Gynecol Scand, 2015, 94: 983-988.
[24] Rahat B, Thakur S, Bagga R, et al. Epigenetic regulation of STAT5A and its role as fetal DNA epigenetic marker during placental development and dysfunction[J]. Placenta, 2016, 44: 46-53.
[25] Zadora J, Singh M, Herse F, et al. Disturbed placental imprinting in preeclampsia leads to altered expression of DLX5, a human-specific early trophoblast marker[J]. Circulation, 2017, 136: 1824-1839.